Affinage

NKX2-2

Homeobox protein Nkx-2.2 · UniProt O95096

Length
273 aa
Mass
30.1 kDa
Annotated
2026-04-29
100 papers in source corpus 36 papers cited in narrative 36 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NKX2-2 is a homeodomain transcription factor that functions principally as a transcriptional repressor to specify cell identity in the developing nervous system, pancreas, and intestine. In the ventral neural tube, NKX2-2 acts downstream of Sonic hedgehog to specify V3 interneurons, serotonergic neurons, and oligodendrocytes by repressing alternative fates; it physically interacts with Olig2 to establish progenitor domain boundaries and directly represses target promoters (Pdgfra, MBP, Sirt2) by recruiting an HDAC1–mSin3A co-repressor complex, with its N-terminal Tinman domain recruiting GRG3/Groucho and its C-terminal domain recruiting HDAC1 and DNMT3A (PMID:10217145, PMID:11526078, PMID:14573534, PMID:15695521, PMID:31932307). In pancreatic endocrine progenitors downstream of Neurog3, NKX2-2 directs beta-cell differentiation by directly occupying and activating beta-cell genes (insulin, MafA, NeuroD1) while repressing alternative-fate genes such as Arx through a DNMT3A–GRG3–HDAC1 repression complex at methylated promoters; its NK2-specific domain confers pancreas-specific functions dispensable for CNS development, and the cofactor KLF4 directs NKX2-2 to alpha-cell-specific promoters (PMID:9584121, PMID:22056672, PMID:28071588, PMID:37364986, PMID:39797760). Loss-of-function mutations in NKX2-2 cause permanent neonatal diabetes in humans (PMID:24411943).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 1998 High

    Establishing that NKX2-2 is required for terminal beta-cell differentiation resolved the question of which transcription factors drive the final steps of insulin-producing cell maturation in the pancreas.

    Evidence Nkx2.2 null mouse showing failure of beta-cell precursors to express Glut2, Nkx6.1, and mature insulin, with neonatal diabetes

    PMID:9584121

    Open questions at the time
    • Mechanism of NKX2-2 action (activator vs. repressor) unknown
    • Direct transcriptional targets not identified
    • Relationship to other endocrine lineage transcription factors undefined
  2. 1999 High

    Demonstrating that NKX2-2 interprets graded Shh signaling to specify V3 interneuron identity established a dual tissue role for NKX2-2 and revealed it acts as a binary cell-fate switch in ventral neural tube patterning.

    Evidence Nkx2.2 null mouse showing ventral-to-dorsal fate transformation with motor neuron generation instead of V3 interneurons

    PMID:10217145

    Open questions at the time
    • Whether NKX2-2 acts as an activator or repressor of neural fate genes unknown
    • Redundancy with Nkx2.9 not addressed
  3. 2001 High

    Showing that NKX2-2 controls oligodendrocyte differentiation timing—both alone and cooperatively with Olig2—expanded its neural role from neuronal to glial fate specification and established its repressor function in the CNS.

    Evidence Nkx2.2 null mouse with delayed oligodendrocyte maturation; Olig2+Nkx2.2 co-expression driving ectopic OPC differentiation in chick spinal cord

    PMID:11526078 PMID:11567617

    Open questions at the time
    • Direct target genes mediating oligodendrocyte maturation not identified
    • Physical interaction between Olig2 and NKX2-2 not yet demonstrated
  4. 2002 High

    ChIP demonstration that NKX2-2 directly occupies beta-cell gene regulatory regions (insulin, IAPP, Pax4, glucokinase) in vivo established it as a direct transcriptional regulator rather than an indirect developmental signal.

    Evidence Chromatin immunoprecipitation from intact beta cells plus EMSA and reporter assays

    PMID:12426319

    Open questions at the time
    • Whether NKX2-2 activates or represses each target not resolved
    • Co-factors mediating target selectivity unknown
  5. 2003 High

    Identifying a physical NKX2-2–Olig2 complex provided the molecular basis for the cross-repressive interaction that establishes the pMN–p3 progenitor domain boundary in the spinal cord.

    Evidence Reciprocal co-immunoprecipitation and yeast two-hybrid with specificity controls (no binding to Nkx6.1 or NeuroD)

    PMID:14573534

    Open questions at the time
    • Domain of interaction not mapped
    • Functional consequence of disrupting the complex not tested in vivo
  6. 2003 High

    Placing NKX2-2 in an epistatic cascade with Lmx1b and Pet-1 for serotonergic neuron specification defined a minimal transcription factor code sufficient to drive serotonin cell fate.

    Evidence Lmx1b null mouse plus ectopic co-expression of Nkx2.2+Lmx1b+Pet-1 driving 5-HT differentiation in chick dorsal spinal cord

    PMID:14602809

    Open questions at the time
    • Direct transcriptional targets of NKX2-2 in serotonergic specification unknown
    • Whether NKX2-2 directly activates Lmx1b or Pet-1 not tested
  7. 2005 High

    Elucidating NKX2-2's repression mechanism at the MBP promoter—recruitment of an HDAC1–mSin3A complex and competition with activators Puralpha and Sp1—provided the first molecular model for how NKX2-2 controls differentiation timing in oligodendrocyte progenitors.

    Evidence In vitro DNA binding, co-immunoprecipitation of HDAC1–mSin3A complex, Sp1 competition assays, reporter assays

    PMID:15695521

    Open questions at the time
    • In vivo validation of Sp1 competition mechanism not performed
    • Whether the same co-repressor complex operates in neural tube patterning unknown
  8. 2006 High

    Identifying NKX2-2 as a critical EWS/FLI target gene necessary for Ewing sarcoma oncogenesis revealed a disease context in which NKX2-2's repressor activity is co-opted for transformation.

    Evidence RNAi knockdown of NKX2-2 abolishing tumorigenic phenotype of Ewing sarcoma cells, with rescue by re-expression

    PMID:16697960

    Open questions at the time
    • Direct transcriptional targets mediating oncogenic transformation not identified
    • Whether NKX2-2 repressor or activator function drives oncogenesis not resolved
  9. 2007 High

    Demonstrating that an Engrailed-repressor derivative of NKX2-2 rescues alpha- and partially beta-cell development in null mice, combined with mapping the GRG3 interaction to the Tinman domain, established that NKX2-2's pancreatic function is predominantly repressive.

    Evidence Transgenic dominant-derivative rescue in Nkx2.2 null mice; Co-IP mapping GRG3–Tinman domain interaction

    PMID:17202186

    Open questions at the time
    • Why beta-cell rescue is incomplete not explained
    • Whether NKX2-2 also has essential activator functions in beta cells not excluded
  10. 2008 High

    Structure-function dissection in Ewing sarcoma confirmed that the DNA-binding and repressor domains—but not the activation domain—are required for NKX2-2-mediated oncogenesis, and identified TLE/Groucho and HDAC as recruited co-repressors at direct target loci.

    Evidence Domain mutagenesis, ChIP-chip, pharmacological HDAC/TLE blockade, reporter assays in Ewing sarcoma cells

    PMID:18414662

    Open questions at the time
    • Specific target genes driving oncogenesis not individually validated
    • Whether TLE and HDAC are recruited to the same or distinct target sets unclear
  11. 2010 High

    Showing that NKX2-2 and NKX2-9 redundantly repress the motor neuron program (including Olig2) in the p3 domain resolved why single NKX2-2 mutants retained partial V3 interneuron specification.

    Evidence Nkx2.2/Nkx2.9 double-mutant mouse with complete loss of V3 interneurons and conversion to motor neuron fate

    PMID:21068056

    Open questions at the time
    • Whether NKX2-9 uses the same co-repressor complexes as NKX2-2 untested
    • Direct target gene overlap between NKX2-2 and NKX2-9 not mapped
  12. 2011 High

    Identifying a DNMT3A–GRG3–HDAC1 repression complex recruited by NKX2-2 to the methylated Arx promoter in beta cells provided the molecular mechanism for NKX2-2-mediated beta-versus-alpha cell fate maintenance through epigenetic silencing.

    Evidence Co-IP of NKX2-2 with DNMT3A, GRG3, HDAC1; Tinman domain knock-in mutation in mice; beta-cell-specific DNMT3A deletion; Arx removal rescue; ChIP at Arx promoter

    PMID:22056672

    Open questions at the time
    • Whether NKX2-2 recruits DNMT3A to additional targets beyond Arx unknown
    • How DNA methylation state feeds back on NKX2-2 binding not addressed
  13. 2014 High

    Direct ChIP binding of NKX2-2 to the Pdgfra promoter, combined with conditional KO and genetic epistasis, established Pdgfra repression as the key mechanism by which NKX2-2 controls oligodendrocyte differentiation timing.

    Evidence Conditional NKX2-2 KO delaying OPC maturation; NKX2-2 overexpression accelerating it; ChIP showing direct Pdgfra binding; Pdgfra ablation phenocopying NKX2-2 overexpression

    PMID:24449836

    Open questions at the time
    • Whether NKX2-2 represses Pdgfra via the same HDAC1 complex used at MBP/Sirt2 not tested
    • Post-translational regulation of NKX2-2 during OPC maturation unknown
  14. 2014 Medium

    Identification of homozygous NKX2-2 mutations in patients with permanent neonatal diabetes confirmed the conserved requirement for NKX2-2 in human beta-cell development.

    Evidence Homozygosity mapping and Sanger sequencing in consanguineous families with neonatal diabetes

    PMID:24411943

    Open questions at the time
    • Functional validation of specific patient mutations not performed
    • Whether heterozygous carriers have subclinical phenotypes not assessed
  15. 2017 High

    Neurog3-Cre conditional deletion recapitulating the full null pancreatic phenotype established that NKX2-2 functions specifically within endocrine progenitors downstream of Neurog3, rather than in earlier pancreatic progenitors.

    Evidence Neurog3-Cre-specific Nkx2.2 conditional knockout in mice with immunohistochemistry and gene expression analysis

    PMID:28071588

    Open questions at the time
    • Whether NKX2-2 has any function in pre-Neurog3 progenitors at subthreshold levels not excluded
    • Direct NKX2-2 targets in the endocrine progenitor transcriptome not comprehensively mapped
  16. 2020 High

    Domain dissection showing that the Tinman domain recruits GRG3 while the C-terminal domain independently recruits HDAC1 and DNMT3A—with the NK2-specific domain suppressing C-terminal function—revealed a modular co-repressor architecture that explains tissue-specific NKX2-2 activity.

    Evidence Co-IP with domain deletions, in ovo chick spinal cord electroporation assays for oligodendrocyte differentiation

    PMID:31932307

    Open questions at the time
    • Crystal structure of NKX2-2 with co-repressors unavailable
    • How the NK2-SD suppresses C-terminal domain function mechanistically undefined
  17. 2023 High

    Endogenous NK2-specific domain mutation selectively impaired beta-cell maturation while sparing CNS functions, establishing that the SD confers pancreas-specific NKX2-2 activity, potentially via chromatin remodeler and nuclear pore complex interactions.

    Evidence Endogenous SD knock-in mutation in mice with parallel beta-cell and CNS phenotyping; proteomics identifying candidate SD interactors

    PMID:37364986

    Open questions at the time
    • SD-interacting chromatin remodelers not individually validated for functional relevance
    • Whether SD interactions are direct or bridged not resolved
  18. 2025 High

    Identifying KLF4 as a cofactor that directs NKX2-2 occupancy to alpha-cell-specific promoters revealed how the same transcription factor achieves cell-type-specific target selection within the pancreatic islet.

    Evidence ChIP-seq co-occupancy of NKX2-2 and KLF4; conditional KLF4 KO reducing NKX2-2 binding; KLF4 overexpression in beta cells opening alpha-cell chromatin and recruiting NKX2-2

    PMID:39797760

    Open questions at the time
    • Whether additional cell-type-specific cofactors direct NKX2-2 in beta cells or CNS unknown
    • Genome-wide NKX2-2 target comparison across all expressing cell types not performed

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis for NKX2-2's modular co-repressor recruitment, the complete set of cell-type-specific cofactors directing its genomic occupancy, and the mechanism by which the NK2-specific domain suppresses C-terminal repressor function remain unresolved.
  • No structural model of NKX2-2 in complex with GRG3, HDAC1, or DNMT3A
  • Complete genome-wide target comparison across NKX2-2-expressing tissues not available
  • Post-translational regulation of NKX2-2 activity largely unexplored

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 8 GO:0003677 DNA binding 4
Localization
GO:0005634 nucleus 2
Pathway
R-HSA-1266738 Developmental Biology 6 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-1643685 Disease 4 R-HSA-4839726 Chromatin organization 3 R-HSA-162582 Signal Transduction 2
Partners
CHD4DNMT3AGRG3HDAC1KLF4MSIN3AOLIG2PAX4
Complex memberships
NKX2-2–GRG3–HDAC1–DNMT3A repression complexNKX2-2–HDAC1–mSin3A co-repressor complexNKX2-2–Olig2 complex

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 Nkx2.2 is required for interpreting graded Sonic hedgehog signals and specifying ventral interneuron identity in the neural tube; in Nkx2.2 mutants, progenitor cells undergo a ventral-to-dorsal fate transformation and generate motor neurons rather than V3 interneurons, demonstrating Nkx2.2 has a primary role in neuronal patterning downstream of Shh. Genetic loss-of-function (Nkx2.2 null mouse), immunohistochemistry, in situ hybridization for cell-type markers Nature High 10217145
1998 Nkx2.2 is required for the final differentiation of pancreatic beta cells; in its absence, beta-cell precursors expressing IAPP and Pdx1 fail to complete differentiation and lack Glut2 and Nkx6.1, resulting in severe neonatal hyperglycemia and death. Genetic loss-of-function (Nkx2.2 null mouse), immunohistochemistry, in situ hybridization Development High 9584121
2001 Coexpression of Olig2 with Nkx2.2 in the spinal cord promotes ectopic and precocious oligodendrocyte differentiation; both proteins function as transcriptional repressors in this context, and the effect is blocked by Neurogenin1. In vivo misexpression/overexpression in chick spinal cord, reporter assays, loss-of-function analysis Neuron High 11567617
2001 Nkx2.2 controls the differentiation and maturation of oligodendrocyte progenitors; loss of Nkx2.2 dramatically retards MBP+ and PLP-DM20+ oligodendrocyte differentiation, and overproduction of Nkx2.2 in fibroblasts can induce PLP promoter expression, demonstrating direct regulation of oligodendrocyte differentiation. Nkx2.2 null mouse loss-of-function, in vitro overexpression/reporter assay, immunohistochemistry Development High 11526078
2000 Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation; Nkx6.1/Nkx2.2 double mutant islet development is identical to Nkx2.2 single mutant, placing Nkx6.1 downstream of Nkx2.2 via genetic epistasis. Genetic epistasis — Nkx6.1/Nkx2.2 double-mutant mouse analysis, immunohistochemistry Development High 11076772
2006 NKX2.2 is a critical target gene of EWS/FLI in Ewing's sarcoma; ongoing EWS/FLI expression induces NKX2.2, and NKX2.2 is necessary for the tumorigenic/oncogenic transformation phenotype of Ewing's sarcoma cells. Retroviral-mediated RNA interference knockdown, reexpression studies, gene expression profiling Cancer Cell High 16697960
2008 NKX2.2 mediates transcriptional repression downstream of EWS/FLI in Ewing's sarcoma; the DNA-binding and repressor domains are required for oncogenesis while the activation domain is dispensable; NKX2.2 recruits TLE (Groucho) and HDAC co-repressors; ChIP-chip confirmed direct binding of NKX2.2 to repressed target gene loci. Structure-function mutagenesis, microarray, ChIP-chip, pharmacological blockade of TLE/HDAC, reporter assays PLoS ONE High 18414662
2011 Nkx2.2 forms a large repression complex in pancreatic beta cells that includes DNMT3a, Grg3, and HDAC1; the Tinman (TN) domain of Nkx2.2 mediates interaction with Grg3; Nkx2.2 preferentially recruits Grg3 and HDAC1 to the methylated Arx promoter in beta cells to repress Arx and prevent beta-to-alpha cell transdifferentiation. Co-immunoprecipitation, endogenous TN-domain knock-in mutation in mice, beta-cell-specific DNMT3a deletion, Arx removal rescue experiment, ChIP Genes & Development High 22056672
2003 Olig2 forms a physical protein complex with Nkx2.2 in mammalian cells and yeast two-hybrid assays; this interaction is specific (Olig2 does not bind Nkx6.1; Nkx2.2 does not bind NeuroD); physical complex formation underlies the cross-repressive interaction that establishes the pMN-p3 boundary in the developing spinal cord. Co-immunoprecipitation, yeast two-hybrid, deletion mapping Journal of Neuroscience High 14573534
2014 Nkx2.2 is a key regulator of the timing of oligodendrocyte differentiation; induced Nkx2.2 expression causes precocious OPC differentiation while conditional ablation delays maturation; Nkx2.2 directly binds the Pdgfra promoter and represses its expression; genetic ablation of Pdgfra mimics Nkx2.2 overexpression in accelerating OPC differentiation. Conditional knockout, overexpression, ChIP (Nkx2.2 binding to Pdgfra promoter), genetic epistasis (Pdgfra ablation) Development High 24449836
2003 Lmx1b and Pet-1 act downstream of Nkx2.2 to specify the serotonergic neurotransmitter phenotype; ectopic expression of all three (Lmx1b + Pet-1 + Nkx2.2) drives 5-HT differentiation in dorsal spinal cord, defining a molecular pathway necessary and sufficient for serotonergic fate. Genetic loss-of-function (Lmx1b null mice), ectopic gain-of-function in chick spinal cord, epistasis analysis Journal of Neuroscience High 14602809
2005 Nkx2.2 represses myelin basic protein (MBP) gene expression in oligodendrocyte progenitors by binding two regulatory elements in the MBP promoter, recruiting an HDAC1-mSin3A co-repressor complex, and blocking binding of the activator Puralpha; Sp1 can compete off Nkx2.2 binding and reverse repression, thereby allowing MBP expression in mature oligodendrocytes. In vitro DNA binding assays, promoter reporter assays, co-immunoprecipitation (HDAC1-mSin3A complex), competition assays Journal of Biological Chemistry High 15695521
2007 Nkx2.2 repressor activity (via Engrailed-repressor fusion) is sufficient to fully rescue glucagon-producing alpha-cells and partially rescue beta-cells in Nkx2.2 null mice; Grg3 physically interacts with Nkx2.2 through its TN domain in the embryonic pancreas, mediating co-repressor function. Transgenic dominant-derivative rescue in Nkx2.2 null mice, co-immunoprecipitation (Nkx2.2-Grg3 interaction via TN domain), immunohistochemistry Development High 17202186
2009 Nkx2.2 cooperatively activates NeuroD1 transcription with Ngn3; Nkx2.2 directly binds one NeuroD1 promoter element and indirectly regulates another; Nkx2.2 is necessary to maintain high NeuroD1 expression in developing islets and mature beta cells, placing Nkx2.2 upstream of NeuroD1. Genetic loss-of-function (Nkx2.2 null mouse and zebrafish morpholino), ChIP, reporter assays, promoter mutagenesis Journal of Biological Chemistry High 19759004
2002 Nkx2.2 directly occupies insulin gene control region sequences in intact beta cells in vivo; Nkx2.2 also binds to regulatory regions of islet amyloid polypeptide, Pax4, and glucokinase genes in vivo, demonstrating direct transcriptional regulation of multiple islet beta-cell genes. Chromatin immunoprecipitation (ChIP) from intact beta cells, in vitro DNA binding (EMSA), transient transfection reporter assays Journal of Biological Chemistry High 12426319
2007 Nkx2.2 is required in the mature beta cell for maintenance of MafA and Glut2 expression, insulin gene expression, pancreatic insulin content, and glucose-stimulated insulin secretion; a dominant repressor derivative of Nkx2.2 disrupts endogenous Nkx2.2 function in adult beta cells, causing glucose intolerance and diabetes. Transgenic mouse overexpression of Nkx2.2 repressor derivative in adult beta cells, metabolic phenotyping, gene expression analysis Diabetes High 17456846
2006 FoxA2, Nkx2.2, and PDX-1 directly bind a conserved beta-cell-specific region (region 3, bp -8118 to -7750) of the mafA promoter in vivo and cooperatively activate mafA transcription; Nkx2.2 binding at bp -7771 to -7746 mediates region 3 activation. ChIP, reporter assays, promoter mutagenesis, siRNA knockdown of PDX-1 Molecular and Cellular Biology High 16847327
2011 Nkx2.2 directly binds the Sirt2 promoter via HDAC1 in oligodendroglial precursor (CG4) cells, negatively regulating Sirt2 expression; HDAC1 knockdown attenuates Nkx2.2 binding and releases Sirt2 repression; Nkx2.2 overexpression down-regulates Sirt2 and delays CG4 cell differentiation. ChIP (Nkx2.2 and HDAC1 binding to Sirt2 promoter), siRNA knockdown of HDAC1, overexpression of Nkx2.2 and Sirt2 in CG4 cells, reporter assays Journal of Molecular Cell Biology High 21669943
2010 Nkx2.2 and Nkx2.9 are required together to establish V3 interneuron fate by repressing the motor neuron lineage program (including Olig2) in the p3 domain; double mutant mice lack V3 interneurons and show conversion to motor neuron fate; additionally, both factors are required for floor plate development and commissural axon guidance. Nkx2.2/Nkx2.9 double-mutant mouse, cell fate analysis, axon tracing, locomotor activity assays Development High 21068056
2000 The homeodomain of Nkx2.2 contains two cooperatively acting nuclear localization signals (NLS): a proximal NLS (KKRKRR) at the N-terminus of the homeodomain and a distal NLS (RYKMKRAR) at its C-terminus; each NLS is individually sufficient but inefficient for nuclear transport, and both act cooperatively for complete nuclear import. Deletion mutagenesis, nuclear localization assays in transfected cells Biochemical and Biophysical Research Communications Medium 10772886
2004 Pax4 and Nkx2.2 genetically interact to initiate pancreatic beta-cell differentiation; loss of Pax4 prevents expression of Pdx1, HB9, and insulin in beta-cell precursors, and this role is accomplished via genetic interaction with Nkx2.2. Pax4 knockout mouse, immunohistochemistry, genetic interaction analysis Developmental Biology Medium 14729487
2007 Nkx2.2 regulates cell fate choices in intestinal enteroendocrine cell lineages; in Nkx2.2 null mice, several hormone-producing enteroendocrine populations are absent/reduced and ghrelin-producing cells expand; Nkx2.2 functions upstream of Pax6 in intestinal enteroendocrine cell fate. Nkx2.2 null mouse, immunohistochemistry, RT-PCR, Pax6 expression analysis as downstream marker Developmental Biology High 18022152
2017 Nkx2.2 acts primarily downstream of Neurog3 (endocrine progenitor cells) and functions as an integral component of a modular regulatory program to specify pancreatic islet cell fates; Neurog3-Cre-specific deletion of Nkx2.2 recapitulates the full Nkx2.2 null pancreatic phenotype, demonstrating essential activity in the endocrine progenitor population. Neurog3-Cre conditional knockout of Nkx2.2, immunohistochemistry, gene expression analysis eLife High 28071588
2009 Nkx2.2 directly binds to and activates the ghrelin promoter in multiple cell lines; the promoter region between -619 and -488 bp upstream of the translational start site is necessary for repression of ghrelin in alpha and beta cell lines; upregulation of ghrelin in Nkx2.2 null mice is not due to loss of promoter repression but suggests Nkx2.2 contributes to ghrelin activation in epsilon cells. Promoter reporter assays, ChIP, Nkx2.2 null mouse analysis, luciferase deletion constructs Molecular Endocrinology Medium 19965928
2020 NKX2-2 regulates oligodendrocyte differentiation through domain-specific co-repressor interactions: the N-terminal Tinman (TN) domain recruits GRG3, while the C-terminal domain recruits HDAC1 and DNMT3A; these domains synergistically promote oligodendrocyte differentiation; the NK2-specific domain suppresses the C-terminal domain function in oligodendrocyte differentiation. Co-immunoprecipitation, in ovo electroporation in chick spinal cord, domain deletion mutagenesis, immunofluorescence, in situ hybridization Journal of Biological Chemistry High 31932307
2015 NKX2.2 mediates EWS/FLI-controlled repression of mesenchymal features in Ewing sarcoma; NKX2.2 represses cell adhesion and extracellular matrix genes including zyxin; NKX2.2-depleted cells display increased focal adhesions, actin stress fibers, cell spreading, migration, and substrate adhesion. RNA sequencing, NKX2.2 knockdown, immunofluorescence of focal adhesion markers, migration assays Genes & Cancer Medium 26000096
2016 In the intestine, Nkx2.2 regulates enteroendocrine cell specification in a stage-dependent manner; serotonin-producing enterochromaffin cells are most severely reduced in all Nkx2.2 mutant conditions; Lmx1a is expressed in enterochromaffin cells and functions downstream of Nkx2.2; Lmx1a deficiency reduces Tph1 expression. Stage- and cell-type-specific conditional Nkx2.2 deletion, Lmx1a knockout mouse, immunohistochemistry, RT-PCR Development High 27287799
2023 The NK2-specific domain (SD) of NKX2.2 is required for beta-cell-specific functions: SD mutation prevents developmental progression of beta-cell precursors into mature insulin-expressing beta cells and impairs adult beta-cell function; SD-dependent effects may be mediated via interactions with chromatin remodelers and nuclear pore complex components; the SD is dispensable for NKX2.2-dependent CNS cell type development. Endogenous SD knock-in mutation in mice, beta-cell phenotyping, gene expression analysis, proteomics/interaction studies Genes & Development High 37364986
2016 Nuclear import of Nkx2-2 is mediated by multiple pathways: importin alpha1/beta1 (classical pathway), direct importin beta1 binding, and direct importin 13 binding; mutation of NLS1 or NLS2 reduces binding to importin beta1 but not to importin alpha1 or importin 13. Co-immunoprecipitation, GST pull-down, in vitro nuclear import assays, siRNA knockdown of importins, NLS mutagenesis Biochemical and Biophysical Research Communications Medium 27956177
2024 NKX2-2 represses the proneural gene NEUROG2 by two distinct mechanisms in rodent versus human spinal progenitors: in rodents, NKX2-2 represses Olig2 via the Tinman domain leading to loss of Neurog2; in human vpMN progenitors, NKX2-2 represses NEUROG2 but not OLIG2 via a Notch- and Tinman-independent mechanism, allowing protracted motor neurogenesis; ectopic tinman-mutant Nkx2-2 in mouse pMNs phenocopies human vpMNs. In vivo mouse pMN ectopic expression of tinman-mutant Nkx2-2, human and rodent spinal organoid/progenitor analysis, gene expression studies bioRxivpreprint Medium 39415990
2025 CHD4 (chromodomain helicase DNA-binding protein 4) is an NKX2.2 interacting partner identified by unbiased proteomics; CHD4 and NKX2.2 cooperatively bind and repress non-beta-cell genes in beta cells, including Kcnj5 (GIRK4); aberrant GIRK4 upregulation upon Chd4 deletion impairs glucose-stimulated insulin secretion. Unbiased proteomics screen, co-immunoprecipitation, conditional Chd4 beta-cell KO mouse, gene expression analysis, calcium signaling assays bioRxivpreprint Medium 40667117
2025 KLF4 is expressed preferentially in pancreatic alpha cells, co-occupies NKX2.2-bound alpha-cell promoters, is necessary for NKX2.2 promoter occupancy in alpha cells, and coregulates NKX2.2 alpha-cell transcriptional targets; KLF4 overexpression in beta cells manipulates chromatin accessibility and increases NKX2.2 binding at alpha-cell-specific promoters. ChIP-seq (NKX2.2 and KLF4 co-occupancy), conditional/cell-type-specific KO, Klf4 overexpression in beta cells, chromatin accessibility (ATAC-seq) Genes & Development High 39797760
2014 NKX2-2 mutations cause permanent neonatal diabetes in humans, confirming the conserved role of NKX2-2 in human beta-cell development analogous to its role in mice. Homozygosity analysis and Sanger sequencing in consanguineous neonatal diabetes patients; phenotypic comparison to mouse KO Cell Metabolism Medium 24411943
2014 Mammalian Nkx2.2+ perineurial glia are essential for motor nerve development and Schwann cell differentiation; in mice lacking Nkx2.2, motor nerve development is impaired, demonstrating a role for Nkx2.2+ CNS-derived cells in peripheral nervous system formation. Nkx2.2:EGFP transgenic reporter, Nkx2.2 null mouse loss-of-function, immunolabeling, RNA expression analysis Developmental Dynamics Medium 24979729
2011 Nkx2.2 and Arx genetically interact to regulate pancreatic endocrine cell specification; in Nkx2.2 null background, Arx is necessary for ghrelin mRNA upregulation in epsilon cells but not for ghrelin cell expansion; in absence of Arx, Nkx2.2 becomes essential for repression of somatostatin gene expression. Nkx2.2/Arx compound conditional knockout in pancreatic progenitors, immunohistochemistry, RT-PCR Developmental Biology Medium 21856296
2022 Gata2, Nkx2-2, and Skor2 form a transcription factor network regulating development of midbrain GABAergic REM-sleep regulatory neurons; Gata2 is required for Nkx2-2 expression, and both Gata2 and Nkx2-2 are required for Skor2 expression in GABAergic precursors, placing Nkx2-2 downstream of Gata2 and upstream of Skor2. Gata2 and Nkx2-2 conditional knockout mice, immunohistochemistry, REM sleep activity assays, axon projection analysis Development Medium 35815619

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1999 Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling. Nature 604 10217145
1998 Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. Development (Cambridge, England) 512 9584121
2001 The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron 478 11567617
2000 Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major pathway of beta-cell formation in the pancreas. Development (Cambridge, England) 426 11076772
2001 Control of oligodendrocyte differentiation by the Nkx2.2 homeodomain transcription factor. Development (Cambridge, England) 315 11526078
2006 Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer cell 296 16697960
2004 Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Molecular and cellular neurosciences 244 15519240
2002 Dual origin of spinal oligodendrocyte progenitors and evidence for the cooperative role of Olig2 and Nkx2.2 in the control of oligodendrocyte differentiation. Development (Cambridge, England) 177 11830569
2011 Nkx2.2 repressor complex regulates islet β-cell specification and prevents β-to-α-cell reprogramming. Genes & development 164 22056672
2005 Endogenous Nkx2.2+/Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes. Experimental neurology 162 15698615
2017 Genetic evidence that Nkx2.2 acts primarily downstream of Neurog3 in pancreatic endocrine lineage development. eLife 154 28071588
2012 NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma. The American journal of surgical pathology 153 22446943
2016 Evaluation of NKX2-2 expression in round cell sarcomas and other tumors with EWSR1 rearrangement: imperfect specificity for Ewing sarcoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 145 26847175
2003 Lmx1b, Pet-1, and Nkx2.2 coordinately specify serotonergic neurotransmitter phenotype. The Journal of neuroscience : the official journal of the Society for Neuroscience 140 14602809
2014 Genetic evidence that Nkx2.2 and Pdgfra are major determinants of the timing of oligodendrocyte differentiation in the developing CNS. Development (Cambridge, England) 123 24449836
1997 Expression patterns of Brx1 (Rieg gene), Sonic hedgehog, Nkx2.2, Dlx1 and Arx during zona limitans intrathalamica and embryonic ventral lateral geniculate nuclear formation. Mechanisms of development 121 9347917
2008 EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PloS one 119 18414662
2001 Distinct sites of origin of oligodendrocytes and somatic motoneurons in the chick spinal cord: oligodendrocytes arise from Nkx2.2-expressing progenitors by a Shh-dependent mechanism. Development (Cambridge, England) 119 11262237
2004 The concerted activities of Pax4 and Nkx2.2 are essential to initiate pancreatic beta-cell differentiation. Developmental biology 117 14729487
2014 Analysis of transcription factors key for mouse pancreatic development establishes NKX2-2 and MNX1 mutations as causes of neonatal diabetes in man. Cell metabolism 114 24411943
2006 FoxA2, Nkx2.2, and PDX-1 regulate islet beta-cell-specific mafA expression through conserved sequences located between base pairs -8118 and -7750 upstream from the transcription start site. Molecular and cellular biology 102 16847327
2007 Nkx2.2 regulates beta-cell function in the mature islet. Diabetes 85 17456846
2014 The combination of CD99 and NKX2.2, a transcriptional target of EWSR1-FLI1, is highly specific for the diagnosis of Ewing sarcoma. Virchows Archiv : an international journal of pathology 84 25031013
2002 Transcription factor occupancy of the insulin gene in vivo. Evidence for direct regulation by Nkx2.2. The Journal of biological chemistry 81 12426319
2010 Co-localization of Nkx6.2 and Nkx2.2 homeodomain proteins in differentiated myelinating oligodendrocytes. Glia 80 19780200
2007 Nkx2.2 regulates cell fate choice in the enteroendocrine cell lineages of the intestine. Developmental biology 80 18022152
2008 Nkx2.2 antisense RNA overexpression enhanced oligodendrocytic differentiation. Biochemical and biophysical research communications 71 18538132
2010 Regulation of sonic hedgehog-GLI1 downstream target genes PTCH1, Cyclin D2, Plakoglobin, PAX6 and NKX2.2 and their epigenetic status in medulloblastoma and astrocytoma. BMC cancer 70 21059263
2011 Sirt2 is a novel in vivo downstream target of Nkx2.2 and enhances oligodendroglial cell differentiation. Journal of molecular cell biology 67 21669943
2004 Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination. Glia 63 15048854
2007 Nkx2.2-repressor activity is sufficient to specify alpha-cells and a small number of beta-cells in the pancreatic islet. Development (Cambridge, England) 61 17202186
2005 Stage-specific expression of myelin basic protein in oligodendrocytes involves Nkx2.2-mediated repression that is relieved by the Sp1 transcription factor. The Journal of biological chemistry 60 15695521
2006 Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Journal of neuropathology and experimental neurology 59 17146289
2003 Cross-repressive interaction of the Olig2 and Nkx2.2 transcription factors in developing neural tube associated with formation of a specific physical complex. The Journal of neuroscience : the official journal of the Society for Neuroscience 55 14573534
2009 Cooperative transcriptional regulation of the essential pancreatic islet gene NeuroD1 (beta2) by Nkx2.2 and neurogenin 3. The Journal of biological chemistry 51 19759004
2018 NKX2.2 immunohistochemistry in the distinction of Ewing sarcoma from cytomorphologic mimics: Diagnostic utility and pitfalls. Cancer cytopathology 50 30376220
2003 Co-expression pattern of Shh with Prox1 and that of Nkx2.2 with Mash1 in mouse taste bud. Gene expression patterns : GEP 45 12915306
2016 The novel enterochromaffin marker Lmx1a regulates serotonin biosynthesis in enteroendocrine cell lineages downstream of Nkx2.2. Development (Cambridge, England) 42 27287799
2010 The transcription factors Nkx2.2 and Nkx2.9 play a novel role in floor plate development and commissural axon guidance. Development (Cambridge, England) 41 21068056
2011 Nkx2.2 and Arx genetically interact to regulate pancreatic endocrine cell development and endocrine hormone expression. Developmental biology 40 21856296
2017 Usefulness of NKX2.2 Immunohistochemistry for Distinguishing Ewing Sarcoma from Other Sinonasal Small Round Blue Cell Tumors. Head and neck pathology 38 28616785
2015 EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma. Genes & cancer 38 26000096
2005 Differentiation of embryonic stem cells into insulin-producing cells promoted by Nkx2.2 gene transfer. World journal of gastroenterology 36 16015683
2014 Mammalian Nkx2.2+ perineurial glia are essential for motor nerve development. Developmental dynamics : an official publication of the American Association of Anatomists 35 24979729
2008 Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocrine-related cancer 32 18987169
2020 The transcription factor NKX2-2 regulates oligodendrocyte differentiation through domain-specific interactions with transcriptional corepressors. The Journal of biological chemistry 28 31932307
2009 Identification of known and novel pancreas genes expressed downstream of Nkx2.2 during development. BMC developmental biology 27 20003319
2017 Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors. Pathology, research and practice 26 28864350
2011 Arx and Nkx2.2 compound deficiency redirects pancreatic alpha- and beta-cell differentiation to a somatostatin/ghrelin co-expressing cell lineage. BMC developmental biology 25 21880149
2014 C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PloS one 24 24835010
2010 NKX2.2 suppresses self-renewal of glioma-initiating cells. Cancer research 23 21169405
2013 Generation of mice encoding a conditional allele of Nkx2.2. Transgenic research 22 23494546
2011 Ontogenetic distribution of the transcription factor nkx2.2 in the developing forebrain of Xenopus laevis. Frontiers in neuroanatomy 22 21415915
2018 NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomarker research 20 29713473
2013 Nkx2.2:Cre knock-in mouse line: a novel tool for pancreas- and CNS-specific gene deletion. Genesis (New York, N.Y. : 2000) 20 23996959
2015 Nkx2.2 is expressed in a subset of enteroendocrine cells with expanded lineage potential. American journal of physiology. Gastrointestinal and liver physiology 19 26492922
2003 Undulated short-tail deletion mutation in the mouse ablates Pax1 and leads to ectopic activation of neighboring Nkx2-2 in domains that normally express Pax1. Genetics 17 14504237
2000 The homeodomain of Nkx2.2 carries two cooperatively acting nuclear localization signals. Biochemical and biophysical research communications 17 10772886
2018 NKL homeobox gene NKX2-2 is aberrantly expressed in Hodgkin lymphoma. Oncotarget 16 30680064
2018 NKX2-2 Suppresses Osteosarcoma Metastasis and Proliferation by Downregulating Multiple Target Genes. Journal of Cancer 15 30210629
2012 Generation of Nkx2.2:lacZ mice using recombination-mediated cassette exchange technology. Genesis (New York, N.Y. : 2000) 15 22539496
2009 Nkx2.2 activates the ghrelin promoter in pancreatic islet cells. Molecular endocrinology (Baltimore, Md.) 15 19965928
2015 Nkx2.2 and Nkx2.9 are the key regulators to determine cell fate of branchial and visceral motor neurons in caudal hindbrain. PloS one 14 25919494
2020 NKX2-2 Mutation Causes Congenital Diabetes and Infantile Obesity With Paradoxical Glucose-Induced Ghrelin Secretion. The Journal of clinical endocrinology and metabolism 13 32818257
2015 Regulation of the Human Ghrelin Promoter Activity by Transcription Factors, NF-κB and Nkx2.2. International journal of endocrinology 13 25699080
2014 Nato3 plays an integral role in dorsoventral patterning of the spinal cord by segregating floor plate/p3 fates via Nkx2.2 suppression and Foxa2 maintenance. Development (Cambridge, England) 13 24401371
2009 Spatially distinct functions of PAX6 and NKX2.2 during gliogenesis in the ventral spinal cord. Biochemical and biophysical research communications 12 19258013
2023 Major β cell-specific functions of NKX2.2 are mediated via the NK2-specific domain. Genes & development 11 37364986
2022 Gata2, Nkx2-2 and Skor2 form a transcription factor network regulating development of a midbrain GABAergic neuron subtype with characteristics of REM-sleep regulatory neurons. Development (Cambridge, England) 11 35815619
2014 Ceramide galactosyltransferase expression is regulated positively by Nkx2.2 and negatively by OLIG2. Glycobiology 11 24821492
2007 Nkx2.2 expression in differentiation of oligodendrocyte precursor cells and inhibitory factors for differentiation of oligodendrocytes after traumatic spinal cord injury. Journal of neurotrauma 11 17600517
2021 Nkx2-2 expressing taste cells in endoderm-derived taste papillae are committed to the type III lineage. Developmental biology 10 34097879
2010 Genetically-defined lineage tracing of Nkx2.2-expressing cells in chick spinal cord. Developmental biology 10 20951692
2011 Novel computational analysis of protein binding array data identifies direct targets of Nkx2.2 in the pancreas. BMC bioinformatics 9 21352540
2012 Ectopic transgenic expression of NKX2.2 induces differentiation of adult pancreatic progenitors and mediates islet regeneration. Cell cycle (Georgetown, Tex.) 8 22433950
2015 Upregulation of NKX2.2, a target of EWSR1/FLI1 fusion transcript, in primary renal Ewing sarcoma. Journal of cytology 7 25948942
2024 The myelination-associated G protein-coupled receptor 37 is regulated by Zfp488, Nkx2.2, and Sox10 during oligodendrocyte differentiation. Glia 6 38546197
2020 Novel Homeodomain Transcription Factor Nkx2.2 in the Brain Tumor Development. Current cancer drug targets 6 29295693
2015 Generation of a Nkx2.2(Cre) knock-in mouse line: Analysis of cell lineages in the central nervous system. Differentiation; research in biological diversity 6 25840610
2010 Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. The Journal of surgical research 6 20599218
2023 Expression of NKX2.2 in Non-Ewing Tumors With Round Cell Morphology. Cureus 5 38234938
2021 Ewing Sarcoma and Ewing-Like Sarcoma and the Role of NKX2.2 Immunoreactivity. Cureus 5 34584801
2020 Rapid induction of gliogenesis in OLIG2 and NKX2.2-expressing progenitors-derived spheroids. Stem cells translational medicine 5 32716131
2016 Nuclear import of Nkx2-2 is mediated by multiple pathways. Biochemical and biophysical research communications 5 27956177
2024 NKX2-2 based nuclei sorting on frozen human archival pancreas enables the enrichment of islet endocrine populations for single-nucleus RNA sequencing. BMC genomics 4 38689254
2023 Correlation NKX2.2 IHC and EWSR1 break-apart FISH in the diagnosis of Ewing sarcoma: Can combined NKX2.2 and CD99 immunoexpression obviate or minimize the need of FISH testing? First assessment study from Indian tertiary cancer care center. Indian journal of pathology & microbiology 4 36656211
2025 Clinicopathologic Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology. Archives of pathology & laboratory medicine 3 38649148
2024 Differential regulation of Shh-Gli1 cell signalling pathway on homeodomain transcription factors Nkx2.2 and Pax6 during the medulloblastoma genesis. Molecular biology reports 3 39460795
2023 CD99 and NKX2.2 positive neuroblastoma diagnosed on cytology: A potential diagnostic pitfall and necessity of pathological evaluation of the primary site. Diagnostic cytopathology 3 36999306
2023 Differential use of the Nkx2.2 NK2 domain in developing pancreatic islets and neurons. Genes & development 3 37399332
2022 The Roles of Different Multigene Combinations of Pdx1, Ngn3, Sox9, Pax4, and Nkx2.2 in the Reprogramming of Canine ADSCs Into IPCs. Cell transplantation 3 35236160
2012 Nkx2.2+ progenitors generate somatic motoneurons in the chick spinal cord. PloS one 3 23284718
2025 NKX2.2 and KLF4 cooperate to regulate α-cell identity. Genes & development 2 39797760
2023 Role of Gltp in Maturation of Oligodendrocytes Under the Regulation of Nkx2.2. Molecular neurobiology 2 37191854
2025 CHD4 and NKX2.2 Cooperate to Regulate Beta Cell Function by Repressing Non-Beta Cell Gene Programs. bioRxiv : the preprint server for biology 1 40667117
2023 A novel stop-loss mutation in NKX2-2 gene as a cause of neonatal diabetes mellitus: molecular characterization and structural analysis. Acta diabetologica 1 37821536
2022 [Expression and diagnostic value of NKX3.1 and NKX2.2 in mesenchymal chondrosarcoma]. Zhonghua bing li xue za zhi = Chinese journal of pathology 1 35152629
2024 Independent control of neurogenesis and dorsoventral patterning by NKX2-2. bioRxiv : the preprint server for biology 0 39415990
2023 Evaluation of EWSR1/FUS rearrangements by FISH and NKX2.2 immunoexpression in simple bone cysts of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology 0 37891121
2022 Homeodomain Transcription Factors Nkx2.2 and Pax6 as Novel Biomarkers for Meningioma Tumor Treatment. Indian journal of clinical biochemistry : IJCB 0 38223000